Dew... you are sharp enough to know that the pancreatic patients were mostly at the end of the line when they started, with little hope...and with badly compromised immune systems, which don't portend high hopes, particularly for a drug intended to work with the immune system to fight the cancer... you are also sharp enough to know that, since it wasn't a late-stage trial, analysis of subsets, where there were signs of potentially effective treatment compared to soc, it could be worth pursuing given the now-apparent fact that the drug seems to have some efficacy across several afflictions. by focusing on pancreatic, while nsclc and breast both had interesting results, and picking out the weakest of the 3 trials they addressed, your criticism comes across as disingenuous. you and this board both expect more than than from participants here. jeez..one AF is enough...please stay on the higher ground.
nsclc, which is the primary target for now, seems to warrant continuing attention, and i suspect you know it. you do want effective treatments to be developed, don't you? shouldn't all of the new treatments which demonstrate potential effectiveness continue to be pursued till they're shown not to, particularly when it's been such a difficult and underfunded slog with a drug with a new moa that isn't automatically popular since it's so different?
while your bias continues, it looks like it ain't over yet for little ol' pphm.
but they sure could use some money, eh???!!!
AI
